A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Administered By

Awarded By

Contributors

Start/End

  • December 6, 2017 - November 30, 2023